A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

373

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

May 27, 2024

Study Completion Date

May 27, 2024

Conditions
Venous Thromboembolism
Interventions
DRUG

REGN9933

Participants will receive a single dose of REGN9933 by IV infusion

DRUG

Enoxaparin

Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)

DRUG

Apixiban

Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)

Trial Locations (16)

3600

Ziekenhuis Oost-Limburg- Campus Sint-Jan, Genk

5000

MAV Korhaz es Rendelointezet Szolnok, Szolnok

5800

MBAL Heart and Brain Hospital, Pleven

7400

Department of Orthopedics, Somogy County Mór Kaposi Teaching Hospital, Kaposvár

L1S 7K7

Durham Bone and Joint Specialists, Ajax

LV3414

Liepaja Regional Hospital, Liepāja

LV-1002

Vidzemes Hospital, Riga

LV-1004

Riga's 2nd Hospital, Riga

LV1005

Hospital of Traumatology and Orthopaedics, Riga

LT-50009

Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinik, Kaunas

LT-92288

Klaipeda University Hospital, Klaipėda

LT-44320

Lietuvos Sveikatos Mokslu Universiteto Kauno Ligoninė, Kaunas

33-100

Specjalistyczny Szpital im. E. Szczeklika w Tarnowie, Tarnów

90-153

SP ZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz

20-954

Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin

21-300

Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Radzyniu Podlaskim, Radzyń Podlaski

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT05618808 - A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants | Biotech Hunter | Biotech Hunter